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Abstract
Background: Systematic and transparent approaches to priority setting are needed, particularly in low-resource
settings, to produce decisions that are sound and acceptable to stakeholders. The EVIDEM framework brings
together Health Technology Assessment (HTA) and multi-criteria decision analysis (MCDA) by proposing a
comprehensive set of decision criteria together with standardized processes to support decisionmaking. The
objective of the study was to field test the framework for decisionmaking on a screening test by a private health
plan in South Africa.
Methods: Liquid-based cytology (LBC) for cervical cancer screening was selected by the health plan for this field
test. An HTA report structured by decision criterion (14 criteria organized in the MCDA matrix and 4 contextual
criteria) was produced based on a literature review and input from the health plan. During workshop sessions,
committee members 1) weighted each MCDA decision criterion to express their individual perspectives, and 2) to
appraise LBC, assigned scores to each MCDA criterion on the basis of the by-criterion HTA report.
Committee members then considered the potential impacts of four contextual criteria on the use of LBC in the
context of their health plan. Feedback on the framework and process was collected through discussion and from a
questionnaire.
Results: For 9 of the MCDA matrix decision criteria, 89% or more of committee members thought they should
always be considered in decisionmaking. Greatest weights were given to the criteria “Budget impact”, “Cost-
effectiveness” and “Completeness and consistency of reporting evidence”. When appraising LBC for cervical cancer
screening, the committee assigned the highest scores to “Relevance and validity of evidence” and “Disease
severity”. Combination of weights and scores yielded a mean MCDA value estimate of 46% (SD 7%) of the
potential maximum value. Overall, the committee felt the framework brought greater clarity to the decisionmaking
process and was easily adaptable to different types of health interventions.
Conclusions: The EVIDEM framework was easily adapted to evaluating a screening technology in South Africa,
thereby broadening its applicability in healthcare decision making.
Background
In any country, healthcare resource allocation decisions
are complex and involve assessment of the available
scientific evidence, clarification of priorities, value judg-
ments and ethical considerations [1,2]. In developing
countries, which are generally low-resource settings,
priority setting for healthcare becomes even more
important. Not only are resources limited, but there are
also other factors such as poor information, lack of pol-
icy, barriers to implementation, and political agendas, to
name but a few [3]. The result is that priority setting is
inconsistent and unstructured [1]. Transparent and
explicit approaches to decisionmaking help produce
decisions that are sound and acceptable to stakeholders
[4-7].
In the healthcare sector of South Africa, current deci-
sionmaking approaches are centered around evidence-
based medicine, affordability and, where available, cost-
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any medium, provided the original work is properly cited.effectiveness/costutility analysis (CEA/CUA) [8]. Increas-
ingly CEA/CUA is being used for priority setting at all
levels: the patient; the healthcare service; and within
populations. This is evident in the field of HIV/AIDS
where cost-effectiveness analyses of antiretroviral (ARV)
medicines has enhanced access to treatment and reduced
drug prices [9,10]. In many instances, a simple cost-mini-
mization approach is all that is attempted. However, this
approach has shortcomings, as there are a number of
additional important dimensions, such as budget impact,
equity, availability of alternatives, disease severity, etc.
[11,12], that are not incorporated. Where these are taken
into consideration, they are often assessed in an ad hoc
manner and there is a lack of transparency as to how
they impact the final decision [1].
Thus, there is a need for a process that supports con-
sideration of all dimensions impacting a decision in a
systematic and explicit fashion, and increases transpar-
ency and access to the evidence upon which decisions
are based. Multi-criteria decision analysis (MCDA) is a
tool to support complex decisionmaking which allows a
structured, objective consideration of factors that are
both measurable and value-based in an open and trans-
parent manner [1,13,14].
While MCDA has been used historically in sectors
such as transport or agriculture, there is a growing
interest in using and applying the principles of MCDA,
and similar approaches based on multiple decision cri-
teria, to resource allocation decisionmaking in health
care [15-21]. The EVIDEM framework has been devel-
oped to bring together Health Technology Assessment
(HTA) and MCDA by proposing a comprehensive set of
decision criteria together with standardized processes/
methods to develop HTA reports that are structured on
these criteria [22]. The aims of the framework are to
facilitate concurrent consideration of multiple decision
criteria, to stimulate reflection on priorities and values,
and to promote transparency and communication within
the decisionmaking committee as well as with outside
stakeholders. The application of the EVIDEM frame-
work is postulated to be wide ranging from decision-
making by the healthcare provider, to coverage decisions
by the funders or government policy setting.
A proof-of-concept study of the EVIDEM framework
was performed in Canada involving a diverse panel of
stakeholders appraising 10 medicines [23]. The core fra-
mework was also further developed to include standar-
dized contextual criteria and tested for clinical
decisionmaking by a panel of pediatric endocrinologists
and other stakeholders who applied it to appraise
growth hormone for children with Turner syndrome in
Canada [24]. The framework was also tested as a sup-
port for drug formulary decisionmaking by a public
healthcare payer in Canada [25].
The objective of the current study was to expand the
scope of field testing both geographically and with
respect to type of intervention: i.e., to field test the fra-
mework as a support for coverage decisionmaking on a
cervical cancer screening test (liquid-based cytology,
LBC) by a private health plan in South Africa.
The healthcare system in South Africa is dichotomous
with a small (approximately 7 million lives) but
resource-rich private healthcare sector and a growing
(approximately 45 million lives) resource-scarce public
sector. The private healthcare sector is largely funded by
medical insurance companies (health plans), while the
public sector is currently funded out-of-pocket or by the
government. With respect to cervical cancer screening,
the Department of Health guidelines stipulate that all
women should be screened three times in their lifetime
from the age of 30 years [26]. In the private healthcare
sector, cervical cancer screening is often recommended
and carried out on an annual basis. Screening uptake is
low in South Africa with poor accessibility to healthcare
facilities, poorly trained staff, long turnaround times
between laboratory and healthcare facility, as well as
lack of education cited as some of the reasons [27]. LBC
for cervical cancer screening was selected by the health
plan as a relevant case study due to its recent introduc-
tion as an alternative to conventional Pap smears.
Methods
Study design
The EVIDEM framework was field-tested in the private
healthcare sector of South Africa with a clinical policy
and decisionmaking committee of a major health plan.
This panel of experts included doctors (specialists and
general practitioners), pharmacists and nurses with at
least 12 months experience in decision-making at a
health policy level for the health plan. At the time of
the study, the committee was already using evidence-
based medicine, cost-effectiveness, affordability and
some epidemiological principles in a multicriteria-based
decisionmaking process.
The study design is presented in Figure 1. Based on a
literature review and input from the clinical committee
of the health plan, a structured HTA report on LBC for
cervical cancer screening was produced and tailored to
investigate each of the 14 MCDA decision criteria of the
framework organized in the MCDA matrix [22]. (Note
that the framework contains 15 MCDA decision criteria;
however, the criterion “Adherence to requirements of
decisionmaking body” was not considered for appraisal
in this field test.) Four contextual criteria were proposed
by the healthcare funder: “Impact on future decisions”,
“Relationship with pathology providers”, “Impact on
screening intervals” and “Patient expectation"; these cri-
teria were appraised qualitatively. The contents of the
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South African private health plan). Each committee
member was familiarised with the LBC technology
through prior evaluation for clinical decisionmaking
and/or review of the HTA report.
During workshop sessions, committee members
assigned: 1) weights to each criterion of the MCDA
matrix to express their perspectives; 2) scores for LBC
for each criterion of the MCDA matrix based on data
from the by-criterion HTA report; and 3) the qualitative
impact of system-related criteria on the appraisal. The
adoptability and utility of the EVIDEM approach were
explored through a post-testing survey.
Health technology assessment report
Relevant data for each decision criterion of the frame-
work was identified by searching PubMed, websites of
HTA agencies (including the Canadian Agency for
Drugs and Technologies in Health [CADTH], National
Institute for Health and Clinical Excellence [NICE], US
Preventative Services Task Force and Danish Centre for
Evaluation and Health Technology Assessment) and the
website of South Africa’s Department of Health.
Data on the projected budget impact of LBC as well as
local costing data was obtained from the health plan.
The health plan also provided input for the four contex-
tual criteria, which were appraised qualitatively. Col-
lected data was extracted, analyzed and synthesized to
produce a by-criterion HTA report.
The quality of the clinical evidence and the economic
evaluation was assessed using previously developed
instruments according to two quality criteria: “Comple-
teness and consistency or reporting” and “Relevance and
validity of evidence” [22]. The HTA report was entered
into an interactive web prototype (Tikiwiki v2.2) that
was hyperlinked to the full-text sources from which data
Online HTA report (web prototype)
Literature review
Synthesized evidence 
¾For each criterion of 
decision of the framework
Quality assessment
¾Critical analysis of 
key evidence
HTA report 
development 
MCDA Matrix
Step 1: Weight MCDA criteria
Step 2: Score intervention
Discussion and survey
Full testing with 
committee
Case study
Liquid based cytology for cervical cancer screening in South Africa
Impact of qualitative considerations on 
appraisal
Figure 1 Study plan.
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online appraisal of the proposed intervention and collect
feedback from the committee.
Field testing by the committee
To explore their individual values, committee members
were asked to assign weights to each MCDA decision
criterion on a scale of 1 to 5, where 5 represents the
greatest importance to their decisionmaking. Weights
were to be assigned from individual perspectives in the
context of the health plan, independent of the interven-
tion to be appraised.
All committee members were asked to familiarise
themselves with the study intervention (e.g. clinical
trials, health economic studies, disease characteristics
and treatments etc.) using the EVIDEM Synthesised evi-
dence report prior to carrying out the evaluation.
To appraise the proposed intervention, committee
members were then asked to score (on a 4-point scale
from 0 to 3) LBC for cervical cancer screening with
respect to each MCDA criterion of decision, based on
synthesized data from the by-criterion HTA report.
Committee members then considered what type of
impact each of the four qualitative criteria might have
on use of LBC in the context of the health plan.
Feedback on the framework and process was elicited
during discussion periods at the first workshop and at a
follow-up workshop, and from a questionnaire adminis-
tered during the follow-up workshop. Committee mem-
bers were surveyed about whether each of the
framework’s decision criteria should always, sometimes
or never be considered in decisionmaking. They were
also surveyed about how the EVIDEM approach com-
pared to their current process regarding data provided,
deliberative process and communication of decision
(improved, same or worse).
Data collection and analyses
Weights, scores and impact obtained from committee
members were entered into Excel software. Descriptive
statistics were used and mean ± standard deviations
(SD) were calculated for weights and scores. The
MCDA value estimate for the use of LBC in cervical
cancer screening was then obtained by applying an
MCDA linear additive model [22]. Thus, the value con-
tribution of each decision criterion was calculated by
multiplying its mean weight (normalized across the cri-
teria to add up to 1 for each committee member) and
score (standardized by division by the maximum score
3). The MCDA value estimate was then calculated as
the sum of the value contributions of the 14 applicable
criteria of the MCDA matrix.
Results
Decision criteria and committee values
When surveyed on whether each of the criteria of the
framework should always, sometimes or never be con-
sidered in the decisionmaking process, all committee
members agreed that “Budget impact on health plan”
should always be considered (Table 1). For eight further
criteria ("Completeness and consistency of reporting evi-
dence”, “Relevance and validity of evidence”, “Disease
severity”, “Clinical guidelines”, “Improvement of effi-
cacy/effectiveness”, “Type of medical service”, “Cost-
effectiveness” and “Appropriate use”), eight out of nine
(89%) committee members felt that these should always
be considered. Among the 15 MCDA matrix criteria,
“Improvement of PRO, convenience & adherence” and
“Adherence to requirements of decisionmaking body”
received the lowest acceptance from committee mem-
bers, with only 44% and 33%, respectively, indicating
that these should always be considered. “Political con-
text” received least approval among all criteria included
in the survey, with only one (11%) committee member
expressing the opinion that it should always be consid-
ered. No committee member indicated that any criterion
should never be considered.
Committee members were asked to weight each of the
14 MCDA decision criteria included in this field test
according to their importance to the appraisal of an
intervention, independently of the intervention that was
to be appraised. (The criterion “Adherence to require-
ments of decisionmaking body” was not considered for
appraisal in this field test.) The greatest weights (mean
4.7, on a scale of 1 to 5) were assigned to the criteria
“Budget impact on health plan”, “Cost-effectiveness of
intervention” and “Completeness and consistency of
reporting evidence”, followed by “Improvement of effi-
cacy/effectiveness” and “Relevance and validity of evi-
dence” (mean 4.4) (Figure 2). The lowest weights were
given to “Improvement of safety and tolerability” (mean
3.9) and “Public health interest” (mean 3.8). Weights for
“Budget impact on health plan”, “Cost-effectiveness of
intervention” and “Completeness and consistency of
reporting evidence” showed the least variation among
committee members (SD 0.5). The largest divergence of
weights was recorded for the criteria “Size of population
affected” (SD 1.0) and “Public health interest” (SD 1.0).
Appraisal of liquid based cytology for cervical cancer
screening
By-criterion Health Technology Assessment report
The HTA report for LBC was based on 14 references
(Table 2, ‘lite’ version). (The full report is available
online at http://www.evidem.org/tiki/?page=CCLBC-
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reported here. In the context of cervical cancer screen-
ing, LBC refers to a technique in which the cervical
sample is suspended into a preservative liquid, rather
than, as in conventional cytology (CC, Pap test), being
smeared onto a slide. Cervical cancer causes high mor-
bidity and mortality [28-30]. With annual incidence
rates of 9 per 100,000 among white and 40 per 100,000
among black women [31], cervical cancer is the second
most common cause of cancer morbidity and mortality
in South African women [32-34]. Current South African
guidelines recommend screening with at least three cer-
vical Pap smears (CC) per lifetime to detect precancer-
ous lesions; they do not mention LBC [26]. In addition
to the occurrence of unsatisfactory samples, the chief
limitations of CC are its relatively low specificity and
sensitivity and its low uptake by the population
[27,35,36]. There is considerable public health interest
in improving screening methods and uptake to reduce
the high burden of cervical cancer in South Africa
[32,33]. As a screening tool, LBC allows early detection
which, with appropriate treatment, improves outcomes
[30]. A meta-analysis of RCTs found that LBC had 6.4%
higher sensitivity but 4.0% lower specificity than CC,
coupled with a slight reduction in the percentage of
unsatisfactory samples [35]. The most relevant out-
comes, impact on morbidity and mortality due to cervi-
cal cancer, have not been measured. The incremental
budget impact of LBC is estimated to be ZAR76.90 per
patients screened and the incremental colposcopy cost
per patient lifetime ZAR8 [36,37]. The incremental cost
per QALY gained was projected to be ZAR758,000 with
a cost of ZAR764,000 per life-year gained [35]. However,
since these data are based on a Canadian economic eva-
luation model they may have limited relevance to the
South African setting.
Table 1 Committee member responses to whether specific decision criteria should be considered in decision making
Criteria Total number of responses Distribution of responses
Always Sometimes Never
MCDA matrix criteria
Quality of evidence
Adherence to requirements of decision making body 9 33 67 0
Completeness and consistency of reporting evidence 9 89 11 0
Relevance and validity of evidence 9 89 11 0
Disease impact
Disease severity 9 89 11 0
Size of population affected by disease 9 67 33 0
Intervention
Current clinical guidelines 9 89 11 0
Current interventions limitations 9 78 22 0
Improvement of efficacy/effectiveness 9 89 11 0
Improvement of safety & tolerability 9 78 22 0
Improvement of PRO, convenience & adherence 9 44 56 0
Public health interest (prevention & risk reduction) 9 78 22 0
Type of medical service 9 89 11 0
Economics
Budget impact on health plan 9 100 0 0
Cost-effectiveness of intervention 9 89 11 0
Impact on other spending 9 78 22 0
Other criteria
Appropriate use 9 89 11 0
Opportunity costs 9 78 22 0
Organizational structure 9 22 78 0
Stakeholder pressures 9 33 67 0
Political context 9 11 89 0
Population priorities and access 9 22 78 0
Regulatory status of intervention 9 56 44 0
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Using synthesized data from the HTA report in the
MCDA matrix (Table 1), committee members assigned
scores to appraise LBC for each criterion (Figure 3). The
highest scores were assigned to the criteria “Relevance
and validity of evidence” (mean 2.5, SD 0.3, on a scale
of 0 to 3) and “Disease severity” (mean 2.2, SD 0.4). The
lowest scores were given to “Cost-effectiveness of inter-
vention” ( m e a n0 . 3 ,S D0 . 7 ) ,“Improvement of safety &
tolerability” ( m e a n1 . 0 ,S D0 . 0 )a n d“Completeness and
consistency of reporting evidence” ( m e a n1 . 0 ,S D0 . 0 ) .
The committee expressed unanimous agreement (SD
0.0) when scoring the criteria “Improvement of safety &
tolerability” (mean 1.0), “Completeness and consistency
of reporting evidence” (mean 1.0), and “Type of medical
service” (mean 2.0). In contrast, 3-point differences
across the full scoring scale (0 to 3) were seen for the
criteria “Clinical guidelines” (mean 2.0, SD 1.2) and
“Public health interest” (mean 2.0, SD 0.9).
MCDA value estimate
Combination of the committee’s weights and scores
yielded a mean MCDA value estimate for using LBC in
cervical cancer screening of 46% (SD 7%) of the poten-
tial maximum value (Figure 4). Individual MCDA value
estimates ranged from 36% to 61% among the nine
committee members; 7 out of 9 estimates were in the
range between 39% and 48%. The criterion “Relevance
and validity of evidence” made the greatest contribution
to the mean MCDA value estimate (13% of the total),
followed by “Disease severity”, “Clinical guidelines” and
“Type of medical service” (11% each). The criterion
“Cost-effectiveness” made the smallest contribution (2%)
to the MCDA value estimate.
Qualitative considerations - impacts
Background information for the four contextual criteria
proposed by the health plan was collected in the context
of the health plan and provided to the committee to sti-
mulate reflection and discussion (Table 3). Committee
members considered that a decision to cover LBC may
have a negative impact on future decisions (setting a
precedent). When considering relationships with pathol-
ogy providers, covering LBC was considered to have a
positive impact. The possibility of extending screening
intervals would also have a positive impact on the value
of LBC. When considering patient expectations, com-
mittee members considered that patients would likely
resist if co-payments were implemented for LBC.
Feedback from committee on overall approach
A feedback questionnaire was completed by the com-
mittee members following the evaluation. The elements
of the questionnaire were pre-determined and part of
the standardised set of tools available for the EVIDEM
process. When surveyed on how the EVIDEM approach
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Figure 2 Mean weights assigned to each decision criterion of the MCDA matrix by committee members. A five point weighting scale
was used with 1 for lowest weight and 5 for highest weight.
Miot et al. Cost Effectiveness and Resource Allocation 2012, 10:2
http://www.resource-allocation.com/content/10/1/2
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Overview
Disease: Type of intervention: Cervical cytology test
Liquid Based
Cytology (LBC)
Intervention: Indication: Screening for cervical cancer in women
Cervical
cancer
Setting: Administration: Liquid based cytology (LBC) requires physician to obtain
Discovery
Health, South
Africa
cells from the cervix and to place the head of the spatula/brush or rinse it into a vial with preservative fluid. The pathologist then
extracts the cells into a microscopy slide and the cells are examined in the usual way
Comparator(s): Conventional pap smears (i.e., conventional cytology, CC) where the brush containing the sample is smeared onto
the slide, thereby transferring the cells
Data included:Data available from public domain
MCDA matrix
criteria
Highly synthesized information Scoring of intervention
Disease impact Not severe Very severe
D1 Disease severity Disease symptomatic only when spreading from cervix: vaginal
bleeding, post-coital spotting, vaginal discharge, pelvic or low back
pain.
012 3
Late stages: severe anemia, weight loss and uncontrolled release of
urine and feces through the vagina
Survival: < 18 months in 50% of untreated patients
D2 Size of population Incidence in South Africa: 9/100,000 white women; 40/100,000
black women
Very rare
disease
Very common
disease
012 3
Intervention
I1 Clinical guidelines LBC is not included in any guidelines.South African guidelines
recommend at least 3 pap smears test per lifetime
Not
recommended
Strong
recommendation
012 3
I2 Comparative
interventions limitations
Sensitivity: 74% - relatively low; Specificity: 87%;Unsatisfactory
sample: 3%Low screening uptake: 2.8% black women; 18.8% white
women
No or very
minor
limitations
Major limitations
012 3
I3 Improvement of efficacy/
effectiveness
Meta-analyses of RCTs (n = 28,736 vs 39,377): Sensitivity: 80% -
difference with CC = 6.4% (95% CI: -6.5 to 18.8%)Specificity: 82% -
difference with CC = - 4.0% (95% CI: -19.9 to 10.6%) Unsatisfactory
samples: ThinPrep = 2.2% and Sure Path = 0.82%; difference with
CC: ThinPrep = -0.8% and Sure Path = -2.5%
Lower than
comparators
Major
improvement
012 3
I4 Improvement of safety &
tolerability
Safety and tolerability do not differ between LBC and conventional
cytology
Lower than
comparators
Major
improvement
012 3
I5 Improvement of patient
reported outcomes
Patient reported outcomes: No data - fewer recalls and fewer
inadequate specimens with LBC may improve quality of
lifeConvenience: no need to return for HPV testing in case of a
positive result
Lower than
comparators
Major
improvement
012 3
I6 Public health interest Screening programs for cervical cancer in South Africa: mortality
decreased by 50% for white women, 40% for Asian women but rose
for black women between 1960’s 1990’s. and Considerable interest to
improve screening methods and uptake.
No risk
reduction
Major risk
reduction
012 3
I7 Type of medical service Goal of intervention: improve outcome of the disease due to early
detection; 5-years survival ranging between close to 100% for early
stage and 5% to 15% for late stage
Minor Service Major Service (e.
g. cure)
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Figure 3 Mean scores assigned to each decision criterion of the MCDA matrix by committee members for the appraisal of liquid
based cytology. A four point scoring scale was used with 0 for lowest score and 3 for highest score.
Table 2 HTA report with data for each decision criterion of the EVIDEM framework (?’?Lite?’? highly synthesized ver-
sion)* (Continued)
Economics
E1 Budget impact on health
plan
Intervention price: LBC - R180.00; CC - R103.10Incremental cost
per pt screened with LBC: R76.90Annual projected budget
impact per 1000 women: R76,900
Substantial
additional
spending
Substantial
savings
012 3
E2 Cost-effectiveness of
intervention
Cost per life-year gained: R764,000Cost per QALY gained:
R758,000
Not cost-
effective
Highly cost-
effective
012 3
E3 Impact on other
spending
Incremental colposcopy cost per patient over lifetime horizon:R
8
(excludes drug cost, see E1)No available
data on other spending (including treatment of cancer and pre-
cancer)
Substantial
additional
spending
Substantial
Savings
012 3
Quality of evidence
Q1 Adherence to requirements
of decisionmaking body
Not applicable for case study Low
adherence
High adherence
Q2 Completeness and
consistency of reporting
evidence
Quality score: Clinical data:75% - primary and secondary outcome
measures as well as sensitivity analyses not clearly specified;
Economic evaluation: 50% - disaggregated cost not reported;
incomplete reporting of effectiveness outcomes
Many gaps/
inconsistent
Complete &
consistent
012 3
Q3 Relevance and validity of
evidence
Quality score: Clinical data:75% -most relevant outcome not
assessed (morbidity and mortality due to cervical cancer);Economic
evaluation: 75% - Canadian screening coverage and HPV
epidemiology not completely applicable for South African private
payer setting
Low
relevance/
validity
High relevance/
validity
012 3
* The full HTA report is available online at http://www.evidem.org/tiki/?page=CCLBC-RecordMenu
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were familiar with, 50% of the committee members felt
that it improved understanding of the intervention being
appraised, access to quality assessment of the evidence
on the intervention, and consideration of all key ele-
ments of the decision (Table 4). Fifty-six percent of
committee members felt that the framework improved
the transparency of the decision and the communication
Figure 4 M C D Av a l u ee s t i m a t eo fl i q u i db a s e dc y t o l o g yf o rc e r v i c a l cancer screening based on weights and scores assigned by
committee members. Weights were normalized across the 14 criteria and scores are presented on a scale of 0 to 1. *MCDA estimate was
obtained using a linear model combining normalized weights and scores for each decision criteria. For an intervention to achieve close to 1 on
this scale, it would have to cure an endemic disease, demonstrate major improvement in safety, efficacy, and patient reported outcomes
compared to limited existing approaches and result in major healthcare savings.
Table 3 Qualitative considerations and their impact on the appraisal of LBC by committee members
Contextual criteria* Should this be considered?
Would it impact positively or negatively on value of intervention?
Impact on future decisions Decision to fund LBC coverage although not considered cost-effective will be setting a precedent as LBC technology
will be expanded to other cytology tests Considered as negative impact on value
Relationship with pathology
providers
Ongoing negotiations with the pathology groups in other areas may be impacted Considered as a positive impact
on value
Impact on screening intervals Screening interval may be extended to 2 to 3 years than annually Considered as a positive impact on value
Patient expectation Health plan members expect that their pap smears will be paid in full and are likely to resist any benefit design
which implements a co-payment for a more expensive technology Considered as a negative impact on value
*Contextual criteria were proposed by the healthcare funder. Specific contextual criteria may be defined on the basis of the following generic criteria/themes:
mission and scope of the healthcare system, opportunity costs; population priorities & access; system capacity and appropriate use; political context; and
stakeholder pressures.
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Page 9 of 12of the decision to stakeholders. No committee member
rated the EVIDEM process as “worse”.C o n c e r nw a s
raised regarding the time and resources required to gen-
erate the HTA report, but on the whole, the committee
felt it was a positive step forward in improving decision-
making by bringing greater clarity to the decisionmaking
process. The committee also thought that the approach
could easily be applied to evaluation of other health
interventions such as medicines and devices.
The EVIDEM process for LBC resulted in a considera-
tion by the health plan to only fund for LBC up to the
value of conventional pap smears. A negotiation process
was started with the pathology laboratories to review
their tariffs for this diagnostic. The fee for LBC was
reduced to an amount which was considered appropri-
ate for full funding.
Discussion
The EVIDEM framework can be applied to assess the
value of a screening intervention in the South African
private health plan context, providing a practical tool
for integrating HTA with an MCDA approach to sup-
port decisionmaking.
The use of the by-criterion HTA report allowed the
clinical decisionmaking panel to assess all the criteria
easily and from a single source. Where greater detail
was required, hyperlinks embedded in the web-proto-
type provided access to the more detailed synthesized
information as well as full source data. Available clinical
evidence was fairly relevant and valid. Partial reporting
of disaggregated data in the published economic evalua-
tion limited its usefulness in the South African context
although local costs were used to improve transferabil-
ity. The fact that the committee gave the highest weight-
ing to “Budget impact on health plan”, “Cost-
effectiveness of intervention” and “Completeness and
consistency of reporting evidence” reflects its focus on
issues of affordability and cost-effectiveness as well as
quality of clinical evidence.T h i sw a sa l s or e f l e c t e db y
the low score (mean 0.3) the committee assigned to the
cost-effectiveness of LBC (Figure 3), given an ICER of
ZAR764,000 per QALY.
The MCDA estimate resulting from a combination of
weights and scores, provided a comprehensive measure
o ft h ep e r c e i v e dv a l u eo fL B Ci nt h ec u r r e n tc o n t e x t ,i .
e., relative to existing technology (conventional cytol-
ogy), reflecting minor improvement at a significant cost,
and also captured the importance of absolute elements
of value such as disease severity, type of medical service
and quality of evidence.
Non-quantifiable, contextual criteria of decision were
also identified and considered. Given the lack of cost-
effectiveness and high additional cost of LBC compared
to conventional Pap smears, the budget impact would
be substantial and therefore a co-payment would be
considered. However, health plan members and many
other South Africans are used to receiving Pap smears
for free as part of health screening programmes and the
implementation of co-payments would meet with strong
resistance from both patients and healthcare providers.
The use of the MCDA framework as a communication
device to convey the structure and transparency of the
decisionmaking process was thought to be an important
tool to improve acceptability of the committee’s
decision.
Adaptation of the EVIDEM framework from medi-
cines evaluation to a screening technology required
minimal change to the structure of the framework.
Since devices, procedures and technologies form a grow-
ing portion of the basket of healthcare interventions that
require evaluation it was useful to assess the adaptability
of the framework to these types of interventions.
Table 4 Feedback from committee members on the EVIDEM process compared to current approaches
Component Total number of responses Distribution responses (%)
Improved Same Worse
Intervention under scrutiny
Understanding of intervention 8 50 50 0
Access to evidence on intervention 8 25 75 0
Access to quality assessment of evidence on intervention 8 50 50 0
Deliberative process
Considering all key elements of decision 8 50 50 0
Expressing personal/expert opinion 9 11 89 0
Sharing & discussing values among committee members 9 22 78 0
Communication of decision
Transparency of decision 9 56 44 0
Understandability of decision by stakeholders 9 56 44 0
Acceptability of decision by stakeholders 7 43 57 0
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or CADTH) in South Africa with the result that evalua-
tions of new and existing health interventions are scat-
tered and often duplicated. Skilled resources to carry
out a proper HTA are scarce and a need is recognized
for pooling these resources, allowing greater availability
to all sectors in the country [38,39]. Health technology
assessments and reports are freely available from a num-
ber of sources such as NICE (UK), CADTH (Canada),
AHRQ (USA), IQWIG (Germany), etc., as well as
through subscription to knowledge bases such as the
Cochrane Collaboration. However, none of these reports
offers the opportunity to rationally and transparently
measure the impact of the various criteria on the final
clinical decision. This is left to clinical decisionmaking
members who are intrinsically subjective based on their
own priorities and knowledge. Using MCDA in health-
care decisionmaking adopts an existing, well established
methodology based on sound, scientific principles [40].
On the whole, the committee members favoured the
use of the EVIDEM process and were positive about its
use. Some committee members rated their feedback of
the EVIDEM process as “same” as existing process in
the questionnaire, which may be explained by the fact
that a more crude and simpler multicriteria approach
was already being used by the committee.
This field test indicates that the EVIDEM framework
may be useful for the evaluation of health technologies in
the South African private healthcare sector context.
However, further adaptation to a health plan’ss p e c i f i c
mission, scope and priorities is required to create a “cus-
tom-made” decisionmaking framework fully aligned with
the local context. The framework’s contextual tool
("extrinsic value tool”) – ar e s u l to faf u r t h e rd e v e l o p -
ment of this framework [24] – facilitates this customiza-
tion by providing generic criteria/themes on the basis of
which contextual criteria can be identified, and if so
desired, integrated into the MCDA model. Further devel-
opment and validation of the framework’s weighting and
scoring methodologies is also currently underway.
Conclusions
The EVIDEM framework was easily adapted to evaluat-
ing a screening technology thereby broadening its
applicability in healthcare evaluation. It was found to
improve: understanding of intervention; access to quality
assessment of evidence; consideration of key elements of
decision; transparency of decision; and understandability
of decision by stakeholders. Further field testing and
instrument validation and development are ongoing to
collaboratively advance MCDA approaches and contri-
bute to more transparent and efficient healthcare
decisionmaking.
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